Last edition
News about "small cell lung cancer"
Phanes Secures Fast Track Designation for PT217 from FDA
PT217, a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47, is being developed for the treatment of patients with small cell lung cancer (SCLC) and neuroendocrine carcinoma, including neuroendocrine prostate cancer (NEPC).
Small Cell Lung Cancer | 05/12/2024 | By Aishwarya
FDA Approves Amgen's IMDELLTRA for Advanced Small Cell Lung Cancer
The approval is based on the encouraging response rate and duration of response (DoR) observed in clinical studies, under the FDA's accelerated approval pathway.
Small Cell Lung Cancer | 17/05/2024 | By Abha
SN Bioscience's SNB-101 Granted FDA Fast Track Designation for Small Cell Lung Cancer Treatment
SNB-101, previously designated as an orphan drug for SCLC and pancreatic cancer, has now received Fast Track designation, signaling a step towards potential commercialization following the completion of phase 2 clinical trials.
Small Cell Lung Cancer | 10/05/2024 | By Abha | 135
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy